Halozyme Therapeutics (HALO) Shares Repurchased (2019 - 2025)
Historic Shares Repurchased for Halozyme Therapeutics (HALO) over the last 7 years, with Q3 2025 value amounting to $38.9 million.
- Halozyme Therapeutics' Shares Repurchased changed N/A to $38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.9 million, marking a year-over-year increase of 1449.98%. This contributed to the annual value of $250.0 million for FY2024, which is 3787.01% down from last year.
- Latest data reveals that Halozyme Therapeutics reported Shares Repurchased of $38.9 million as of Q3 2025.
- Halozyme Therapeutics' 5-year Shares Repurchased high stood at $252.3 million for Q4 2023, and its period low was $1000.0 during Q4 2022.
- In the last 5 years, Halozyme Therapeutics' Shares Repurchased had a median value of $113.1 million in 2021 and averaged $123.1 million.
- Per our database at Business Quant, Halozyme Therapeutics' Shares Repurchased tumbled by 9999.93% in 2022 and then skyrocketed by 2522990000.0% in 2023.
- Over the past 5 years, Halozyme Therapeutics' Shares Repurchased (Quarter) stood at $150.0 million in 2021, then tumbled by 100.0% to $1000.0 in 2022, then surged by 25229900.0% to $252.3 million in 2023, then dropped by 0.91% to $250.0 million in 2024, then plummeted by 84.45% to $38.9 million in 2025.
- Its Shares Repurchased stands at $38.9 million for Q3 2025, versus $250.0 million for Q4 2024 and $252.3 million for Q4 2023.